

Graham Lappin

List of Publications by Citations

Source: <https://exaly.com/author-pdf/11360531/graham-lappin-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

36
papers

1,410
citations

20
h-index

37
g-index

37
ext. papers

1,534
ext. citations

5.7
avg, IF

4.57
L-index

#	Paper	IF	Citations
36	Big physics, small doses: the use of AMS and PET in human microdosing of development drugs. <i>Nature Reviews Drug Discovery</i> , 2003 , 2, 233-40	64.1	207
35	Use of microdosing to predict pharmacokinetics at the therapeutic dose: experience with 5 drugs. <i>Clinical Pharmacology and Therapeutics</i> , 2006 , 80, 203-15	6.1	191
34	Pharmacokinetics of fexofenadine: evaluation of a microdose and assessment of absolute oral bioavailability. <i>European Journal of Pharmaceutical Sciences</i> , 2010 , 40, 125-31	5.1	95
33	The utility of microdosing over the past 5 years. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2008 , 4, 1499-506	5.5	75
32	Biomedical accelerator mass spectrometry: recent applications in metabolism and pharmacokinetics. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2008 , 4, 1021-33	5.5	69
31	Current perspectives of 14C-isotope measurement in biomedical accelerator mass spectrometry. <i>Analytical and Bioanalytical Chemistry</i> , 2004 , 378, 356-64	4.4	68
30	Microdosing and drug development: past, present and future. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2013 , 9, 817-34	5.5	65
29	The use of isotopes in the determination of absolute bioavailability of drugs in humans. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2006 , 2, 419-27	5.5	63
28	The phase 0 microdosing concept. <i>British Journal of Clinical Pharmacology</i> , 2006 , 61, 367-70	3.8	59
27	The application of accelerator mass spectrometry to absolute bioavailability studies in humans: simultaneous administration of an intravenous microdose of 14C-nelfinavir mesylate solution and oral nelfinavir to healthy volunteers. <i>Journal of Clinical Pharmacology</i> , 2005 , 45, 1198-205	2.9	58
26	Comparative pharmacokinetics between a microdose and therapeutic dose for clarithromycin, sumatriptan, propafenone, paracetamol (acetaminophen), and phenobarbital in human volunteers. <i>European Journal of Pharmaceutical Sciences</i> , 2011 , 43, 141-50	5.1	48
25	A pharmacokinetic evaluation of five H(1) antagonists after an oral and intravenous microdose to human subjects. <i>British Journal of Clinical Pharmacology</i> , 2009 , 67, 288-98	3.8	44
24	The use of accelerator mass spectrometry to obtain early human ADME/PK data. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2005 , 1, 23-31	5.5	40
23	Radiotracers in Drug Development		33
22	Microdosing: current and the future. <i>Bioanalysis</i> , 2010 , 2, 509-17	2.1	32
21	Predicting drug candidate victims of drug-drug interactions, using microdosing. <i>Clinical Pharmacokinetics</i> , 2012 , 51, 237-46	6.2	31
20	A combined accelerator mass spectrometry-positron emission tomography human microdose study with 14C- and 11C-labelled verapamil. <i>Clinical Pharmacokinetics</i> , 2011 , 50, 111-20	6.2	29

19	Addressing metabolite safety during first-in-man studies using ^{11}C -labeled drug and accelerator mass spectrometry. <i>Bioanalysis</i> , 2010 , 2, 1315-24	2.1	24
18	Absolute oral bioavailability and metabolic turnover of ^3H -estrone in healthy subjects. <i>Drug Metabolism and Disposition</i> , 2012 , 40, 2026-30	4	23
17	New ultrasensitive detection technologies and techniques for use in microdosing studies. <i>Bioanalysis</i> , 2009 , 1, 357-66	2.1	23
16	Approaches to intravenous clinical pharmacokinetics: Recent developments with isotopic microtracers. <i>Journal of Clinical Pharmacology</i> , 2016 , 56, 11-23	2.9	20
15	Biotransformation profiling of ^{14}C -labeled xabepilone in human plasma, urine and feces samples using accelerator mass spectrometry (AMS). <i>Drug Metabolism and Pharmacokinetics</i> , 2009 , 24, 511-22	2.2	20
14	Meeting the MIST regulations: human metabolism in Phase I using AMS and a tiered bioanalytical approach. <i>Bioanalysis</i> , 2012 , 4, 407-16	2.1	15
13	AMS method validation for quantitation in pharmacokinetic studies with concomitant extravascular and intravenous administration. <i>Bioanalysis</i> , 2011 , 3, 393-405	2.1	15
12	Ultra-sensitive detection of radiolabelled drugs and their metabolites using accelerator mass spectrometry. <i>Handbook of Analytical Separations</i> , 2003 , 4, 331-349	0.7	11
11	A historical perspective on radioisotopic tracers in metabolism and biochemistry. <i>Bioanalysis</i> , 2015 , 7, 531-40	2.1	10
10	An AMS method to determine analyte recovery from pharmacokinetic studies with concomitant extravascular and intravenous administration. <i>Bioanalysis</i> , 2011 , 3, 407-10	2.1	10
9	Positron emission tomography for use in microdosing studies. <i>Current Opinion in Drug Discovery & Development</i> , 2008 , 11, 104-10		10
8	The expanding utility of microdosing. <i>Clinical Pharmacology in Drug Development</i> , 2015 , 4, 401-6	2.3	9
7	A Review of Human Phase 0 (Microdosing) Clinical Trials Following the US Food and Drug Administration Exploratory Investigational New Drug Studies Guidance. <i>Pharmaceutical Medicine</i> , 2006 , 20, 159-165		9
6	Biomedical Accelerator Mass Spectrometry 2006 , 233-249		1
5	Radioactivity and Radiotracers 2006 , 17-39		1
4	Microdosing: Pharmacokinetic and Metabolism Data Early in the Drug Development Process 2011 , 115-130		1
3	Radiotracers and Drug Registration 2006 , 1-15		0
2	Pharmacokinetics II: ^{14}C -Labelled Microdosing in Assessing Drug Pharmacokinetics at Phase 0 2016 , 151-160		

- 1 Pharmacokinetics II: ^{14}C -labelled microdosing in assessing drug pharmacokinetics at Phase-0 **2010**, 157-166